STUDY DESIGN AND METHODS:
Apheresis lymphocyte collections from patients participating in three CAR T-cell clinical trials were reviewed. Collections were performed on the COBE Spectra by experienced nurses, with the goal of obtaining a minimum of 0.6 3 10 9 and a target of 2 3 10 9 CD31 cells. Preapheresis peripheral blood counts, apheresis parameters, and product cell counts were analyzed.
RESULTS:
Of the 71 collections, 69 (97%) achieved the minimum and 55 (77%) achieved the target. Before apheresis, the 16 patients with yields below the target had significantly lower proportions and absolute numbers of circulating lymphocytes and CD31 lymphocytes and higher proportions of circulating blasts and NK cells than those who achieved the target (470 3 17.6% blasts vs. 4.55% blasts, p 5 0.029). Enrichment of blasts in the product compared to the peripheral blood occurred in four patients, including the two patients whose collections did not yield the minimum number of CD31 cells. Apheresis complications occurred in 11 patients (15%) and, with one exception, were easily managed in the apheresis clinic.
CONCLUSIONS: In most patients undergoing CAR
T-cell therapy, leukapheresis is well tolerated, and adequate numbers of CD31 lymphocytes are collected.
C himeric antigen receptor (CAR) T cells are engineered to bind to tumor-specific cell surface targets, while the adjacent signaling molecules cause T-cell activation, proliferation, and tumor cell lysis. 1, 2 Clinical trials have evaluated the safety and efficacy of CAR T cells for the treatment of acute lymphoblastic leukemia, 2-5 chronic lymphocytic leukemia, 3, [6] [7] [8] diffuse large B-cell lymphoma, 8, 9 multiple myeloma, 10 neuroblastoma, 11 and sarcomas. 12 Results have been so favorable that more than 120 clinical trials are currently open 13 and at least six companies have formed partnerships to produce and study CAR T-cell products; 14 four companies have had initial public offerings worth more than $130 million each. 14 Thus, the therapy appears poised to move from small-scale clinical trials to large-scale commercial production and could become standard treatment for some malignancies in the future. The complex manufacturing process involves obtaining T cells, transducing those cells with a viral vector containing the CAR cassette, and subsequently expanding them in culture. 1 Numerous variables affect the manufacturing process, including the number of starting cells, transduction efficiency, and the ability of the cells to multiply, which in turn may be affected by cell quality, cell purity, 15 culture conditions, and other factors that are as yet unknown (J. Jin, personal communication, 2016). Here, we focused on the essential first step: collection of T cells via apheresis.
Although at least one trial has examined the use of allogeneic T cells, 16 the majority have used autologous T cells.
Apheresis collection of T cells from patients represents a new clinical scenario for practitioners. Historically, peripheral blood mononuclear cell (PBMNC) collections have been performed in two settings: 1) in healthy donors to collect lymphocytes for donor lymphocyte infusions after hematopoietic stem cell transplantation and 2) in leukemic patients with high blast concentrations, to reduce the white blood cell (WBC) concentration and prevent or treat leukostasis. 17, 18 In the former, individuals usually have normal cell counts and the necessary cells are easily obtained; in the latter, the cells being collected-the blasts-are abundant, and the goal of the procedure is their removal rather than their collection. And while autologous peripheral blood stem cell collection in patients with malignancies has been studied, 19 little is known about PBMNC collections for obtaining lymphocytes.
20
Lymphapheresis for CAR T-cell manufacturing involves collecting specific numbers of CD31 lymphocytes from patients. Unlike a donor lymphocyte infusion collection from a healthy donor, patients often have low WBC counts, making it difficult to establish the red blood cell (RBC)-WBC interface in the apheresis centrifuge. 20 Furthermore, underlying disease or prior treatment could affect the properties of the lymphocytes, and typical collection parameters may not be optimal. 20 Finally, patients could have complications such as gastric upset or infection that make them less stable to undergo the procedure. The challenges of collecting CD31 lymphocytes in a population of patients with leukemia and other malignancies have not been well characterized. We evaluated patients undergoing lymphapheresis for the production of CAR T cells to determine the proportion who meet CD31 cell targets, risk factors for inadequate collections, and the rate of adverse events.
MATERIALS AND METHODS

Patients
Inclusion criteria for this study required enrollment in NCT01593696, NCT02315612, or NCT02107963 and lymphocyte collection by apheresis between July 1, 2012, and January 31, 2016. All three trials were single-center, Phase I or II, dose-escalation studies of CAR T-cell therapy for relapsed or treatment-refractory pediatric malignancies. NCT01593696 and NCT02315612 included children with B-cell leukemias and lymphomas that expressed CD19 and CD22, respectively. NCT02107963 included children with solid tumors that expressed GD2. The current retrospective analysis was within the scope of all three trials, which were approved by the National Cancer Institute Institutional Review Board. Data were available for all 71 patients who met the inclusion criteria.
Apheresis
Lymphapheresis procedures were performed on an apheresis machine (COBE Spectra, TerumoBCT) by experienced apheresis nurses collecting at a hematocrit of 2% to 3% and a collection flow rate of 1.0 mL/min. Patients under 18 years old all had central venous catheters (CVCs) placed before the procedure by an experienced vascular access team; those more than 18 years old were assessed to determine whether their peripheral veins were adequate or whether a CVC was needed. During the procedure, all patients received intravenous calcium chloride, prepared and infused according to standard procedures that have been previously described. 21 Patients weighing less than 40 kg also received intravenous magnesium sulfate by methods previously described. 21 The instrument was primed with 1 unit of irradiated, leukoreduced RBCs for all patients weighing less than 20 kg from July 2012 through January 2014 and subsequently for all patients weighing less than 25 kg, due to a change in institution practice. If the patient experienced symptoms of hypocalcemia during the procedure, the calcium infusion rate was increased by 10% to 20%. Patients were required to have stable vital signs, hemoglobin (Hb) concentration greater than 8.0 g/dL, and platelet (PLTs) count of more than 50 3 10 9 /L before apheresis. Limited exceptions were made on a case-bycase basis. As a result, three patients had Hb concentrations of 7 to 8 g/dL and five patients had PLTs of 15 3 10 9 to 50 3 10 9 /L at the time of apheresis.
Laboratory testing
Before apheresis, a complete blood count with automated differential was performed using a hematology analyzer (Sysmex XN-3000, Sysmex America). Manual differentials were performed whenever blasts were detected. Lymphocyte phenotyping was performed by flow cytometric analysis (BD FACSCanto, BD Biosciences); the fraction of lymphocytes that expressed CD3, CD19, or CD16/56 was multiplied by the absolute lymphocyte count to obtain the absolute T-, B-, or NK-cell count, respectively.
After apheresis, a complete blood count performed on the product using a hematology analyzer (Cell-Dyn 3700, Abbott Diagnostics) enabled the determination of the total nucleated cells (TNCs) in the PBMNC concentrate. The Sysmex and Cell-Dyn analyzers were both validated against a standard and used for clinical testing. Cellular phenotypes were determined by flow cytometric analysis using a flow cytometer (BD FACSCanto or BD FACSCanto II, BD Biosciences).
CD31 cell targets
The collections aimed for a minimum of 0.6 3 10 9 and a target of 2 3 10 9 CD31 cells. Although CAR T cells can be manufactured using fewer cells, we have found that a small percentage of cell cultures demonstrate low transduction efficiency or expansion; in our experience, 0.6 3 10 9 CD31
cells often suffices even if such difficulties are encountered, and the target of 2 3 10 9 enables us to cryopreserve extra cells in case a second culture is necessary. 15 The final product was infused using weight-based dosing, and patient weight varied considerably (range, 16 to 140 kg). However, we elected to use a standardized manufacturing method that was independent of the dose required; consequently we targeted a fixed quantity of CD31 cells.
Statistical analysis
The collection efficiency was calculated using the equation:
Efficiency 5 CD31 cell yield ðpreapheresis absolute CD3 1 cells 3 10 6 =L 3 liters processedÞ:
The mean of the absolute CD31 cell counts before and after the procedure was not used because the postapheresis count was not available. Associations between categorical variables were tested using the two-sided Fisher's exact test. Associations between quantitative variables were tested using the two-sided t test. A p value of less than 0.05 was considered significant.
RESULTS
We reviewed 71 autologous apheresis lymphocyte collections for patients who were preparing to receive adoptive immunotherapy therapy with CD19-CAR, CD22-CAR, or GD2-CAR T cells. The majority of the patients were male, carried a diagnosis of acute lymphoblastic leukemia (ALL), and weighed more than 25 kg (Table 1) .
Preapheresis laboratory testing
On average, patients with solid tumors had lower proportions of lymphocytes compared to patients with ALL (p 5 0.02; Table S1 , available as supporting information in the online version of this paper). However, the absolute numbers of lymphocytes were not significantly different between the two groups. Among the 58 patients with ALL, 15 (26%) had detectable circulating blasts on the day of collection (Table S1 ).
Apheresis parameters
The 71 procedures were performed by 12 different apheresis nurses. The majority of patients required CVCs for vascular access (94%) and did not require a blood prime (83%, Table 2 ). The number of total blood volumes processed varied widely. Apheresis complications occurred in 11 patients (15%, Table 2 ) and did not correlate with younger age or lower weight (not shown). One patient with progressive ALL involving the central nervous system developed fever, nausea, vomiting, hallucinations, seizures, and oxygen desaturation. He showed no signs of hypocalcemia during or immediately after the procedure, and his complications were thought to be related to his underlying disease rather than apheresis. He was intubated and transferred to the intensive care unit where he was treated for 19 days before returning to a lower level of care. All other complications were managed in the apheresis clinic, including all paresthesias, which resolved after adjusting the calcium infusion rate.
Collection yields and manufacturing
Only two collections (3%) yielded fewer than 0.6 3 10 9 CD31 cells, the minimum requested for manufacturing. An additional 14 collections (20%) achieved the minimum, but not the target of 2 3 10 9 CD31 cells (Fig. 1A) . Even among 21 patients with low absolute lymphocyte counts (0. Table S2 , available as supporting information in the online version of this paper). TNCs, TNC/kg, differential counts, and number of CD31 cells obtained were highly variable among patients (Table 3) . Peripheral blood CD31 counts were acquired 0 to 11 days before apheresis and correlated with the yield of CD31 cells per liter of blood processed (Fig.  1B) . After the first 48 patients had undergone apheresis, the line of best fit from CD31 cells). Lower apheresis yields were significantly associated with manufacturing failures, which occurred in five of 16 patients (31%) whose PBMNC concentrates contained fewer than the target number of CD31 cells, and three of 55 patients (5%) who met the target (p 5 0.01, not shown).
Risk factors for low CD31 cell collections
A total of 16 PBMNC concentrates contained fewer than the target of 2 3 10 9 CD31 cells. Characteristics such as sex, diagnosis, and clinical trial were not significantly associated with below-target yields (Table S3 , available as supporting information in the online version of this paper). Several laboratory variables, however, showed significant differences when comparing the below-target and above-target groups (Table 4) . Notably, all patients with below-target yields had absolute lymphocyte counts less than 1.5 3 10 9 /L ( Fig. 2A) , and all patients with NK-cell fractions of more than 40% yielded fewer than the targeted number of CD31 cells (Fig. 2B) . There was no significant difference in the CD31 cell collection efficiency between the two groups (Table 4) .
To determine whether the low-yield collections were due to processing inadequate volumes of blood, we reviewed the volume processed for all 16 patients whose collections yielded fewer than 2 3 10 9 CD31 cells (Fig. 3 ).
Less than 3 total blood volumes were processed for eight patients (50%), six of whom had fewer than 10 L processed. Furthermore, five of the eight had CD31 cell counts of less than 500 3 10 6 cells/L. These results suggest that collection targets may have been reached for eight additional patients if the duration of collection had been longer, and they emphasize the importance of customizing the amount of blood processed based on the patient's cell counts.
To determine if enrichment of blasts in the PBMNC concentrate was reducing CD31 cell yields, the proportion of blasts in the circulation and the collected product were compared. Among the 15 patients with circulating blasts, eight had similar proportions in the blood and in the concentrate, differing by less than 10% (Fig. 4) . Decreased proportions of blasts were seen in the concentrate from three patients. Increased proportions were seen in four patients, two of whom had the lowest CD31 cell yields in this study. Those patients are described as case studies below.
Case studies
Patient 029-03 was a 22-year-old, 81-kg male with ALL, who had previously received CD19-CAR T cells and presented for CD22-CAR T cells. On the day of apheresis, his WBC count was 9.88 3 10 9 /L, with 14% lymphocytes and 53% blasts. During the collection, a midprocedure count of TNCs in the concentrate suggested adequate numbers of cells were collected, and the procedure was stopped after 10.6 L of blood was processed. However, the collection bag was later found to contain more than 90% blasts, and only 0.494 3 10 9 CD31 cells. Despite the low yield, culture was initiated; high transduction efficiency and good expansion enabled production of an adequate CD22-CAR T-cell product. Patient 029-09 was a 6-year-old, 21-kg male with ALL, who had previously received CD19-CAR T cells and presented for CD22-CAR T cells. On the day of apheresis, his WBC count was 2.79 3 10 9 /L, with 20% lymphocytes and 26% blasts. Initial flow cytometry testing of the preapheresis peripheral blood showed 63% of the lymphocytes were CD31. During the collection, a midprocedure count of the concentrate was found to contain 61% blasts, 18% NK cells, and only 2% CD31 cells. Despite processing nearly 7 total blood volumes, only 0.288 3 10 9 CD31 cells were obtained. Subsequent investigation led to regating of the preapheresis peripheral blood flow cytometry. The new analysis showed that only 15% of lymphocytes were CD31, and the remainder bore NK-cell markers. Fortunately, additional lymphocytes from the patient were stored at another institution. After shipping the cells to our laboratory, CAR T-cell culture was initiated and manufacturing was successful.
DISCUSSION
We evaluated apheresis lymphocyte collections from 71 patients who were preparing for CAR T-cell immunotherapy. Despite varying levels of leukopenia, the minimum number of CD31 lymphocytes was collected in 97% of patients, and the targeted number in 77% of patients. Apheresis complications occurred in 15% of patients, /L 3 L processed). Abs 5 Absolute; NA 5 not applicable; TBV 5 total blood volumes.
and with one exception, they were easily managed in the apheresis clinic.
Risk factors for low CD31 cell collections included low proportions or absolute numbers of lymphocytes or CD31 cells, high proportions of NK cells, and high proportions of circulating blasts. Patients with these characteristics should be considered at risk of producing an inadequate yield, and in some cases, processing more blood may enable an adequate collection.
The association between high proportions of NK cells and lower CD31 cell collection yields in most cases is likely due to the inverse relationship between NK and CD31 cells as fractions of lymphocytes. Both should separate into the lymphocyte layer in the centrifuge, and more NK cells typically implies fewer CD31 cells.
The association between high proportions of blasts and lower CD31 cell collection yields may be due to lower numbers of circulating CD31 cells or to enrichment of blasts in the PBMNC concentrate. Although the proportion of blasts in the apheresis product was often concordant with the peripheral blood, some patients showed discrepancies. Increasing fractions of lymphoblasts in the apheresis product may have been due to the physical properties of the cells causing them to accumulate in the lymphocyte layer during centrifugation. Alternatively, it could be the result of real increases in circulating blasts during the procedure due to mobilization from the marrow, liver, spleen, or lymph nodes.
The peripheral blood CD31 cell count can be used to predict the yield per liter of blood processed (Fig. 1B) , which can then assist in tailoring the length of the apheresis procedure to the patient. These findings are consistent with previous studies that have shown correlations between preapheresis CD341 cell counts and CD341 cell collection yields in pediatric patients and donors. 21 Careful gating during flow cytometry analysis is essential to accurate determination of the CD31 cell concentration. When the default lymphocyte gating is used, the fraction of CD31 cells can appear falsely elevated. While obtaining adequate quantities of CD31 cells is important to producing sufficient quantities of CAR T cells, it is not the only factor. Early in manufacturing, we observed that CAR T cells from some patients failed to expand in culture, and this phenomenon was associated with PBMNC concentrates containing greater quantities of myeloid cells. 15 Our initial manufacturing protocol, which included a step to enrich PBMNC concentrates for T cells by selection with anti-CD3/CD28 beads, 22 was modified to include a step that depleted myeloid cells by plastic adherence. We are also evaluating more rigorous methods of lymphocyte enrichment including counterflow elutriation and selection with anti-CD4 and anti-CD8 paramagnetic particles. Better enrichment of PBMNC concentrates for T cells may reduce the incidence of manufacturing failures particularly for PBMNC concentrates with low quantities of CD31 cells and large quantities of contaminating cells. As CAR T cells become more widely utilized, commercial groups will likely provide the product throughout the United States. To minimize patient travel, regional apheresis sites will be required and will need standardized yet flexible collection variables that can be personalized for each patient. Based on the data described here, we recommend the cell processing facility specify the targeted yield of CD31 cells. Using the preapheresis CD31 cell count and graphical data similar to those presented in Fig.  1B , the number of liters to be processed can be extrapolated. Care must be taken to obtain accurate CD31 cell counts. Patients weighing more than 40 kg should generally have a minimum of 10 L and a maximum of 24 L processed. Patients with smaller body mass should have a minimum of 3 and a maximum of 6 total blood volumes processed. Patients with circulating blasts should be considered high risk for inadequate collections; processing additional blood may be advisable and midprocedure counts of the PBMNC concentrate should be utilized. Additional research will provide greater understanding regarding the collection and manufacturing processes for CAR T cells. In this study, all procedures were performed on the COBE Spectra, which will not be supported after December 31, 2017. Future collections will likely be performed on the Spectra Optia (TerumoBCT) or Amicus (Fenwal) instruments, and comparisons of the different instruments will be important. Furthermore, this study addresses only quantity of CD31 cells for subsequent manufacturing; quality of the CD31 cells, purity of the apheresis collection, 15 and other variables that affect the manufacturing process will require extensive evaluation. Collection of adequate numbers of CD31 cells for CAR T-cell manufacturing is safe and feasible in the majority of patients. Longer collection procedures may facilitate increased CD31 cell yields in patients who are at risk of low yields. As CAR T cells become more widely used, understanding different variables that affect the lymphocyte collection will aid in ensuring that all patients can have sufficient cells for manufacturing. A personalized approach to the collection process is the essential first step for CAR T-cell immunotherapy.
ACKNOWLEDGMENTS
The authors thank the patients and family members who enrolled in NCI protocols 12-C-0112, 14-C-0059, and 15-C-0029. We 
WEB RESOURCES
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article at the publisher's website: Table S1 . Patient pre-apheresis laboratory values Table S2 . Demographics, laboratory values, and apheresis yields in 21 patients with absolute lymphocyte counts 0.5x10 3 /mL, CD31 cells 300/mL, or both Table S3 . Association between baseline characteristics and CD31 cell yield
